{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:02:31Z","timestamp":1771945351235,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]},{"name":"Grant from National Academy of Medical Sciences of Ukraine","award":["0123U100771"],"award-info":[{"award-number":["0123U100771"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This exploratory, single-group, open-label study investigated 17 patients with Parkinson\u2019s disease (PD) using a pre-post design. Motor and non-motor outcomes were assessed through clinical scales, biochemical and genetic analyses, and machine learning models (Gradient Boosting Machines, Random Forests). After treatment with a neurotrophic peptide mixture, improvements were observed in daily activity (16%), cognition (11%), depression (10% reduction), and reactive anxiety (23% reduction). Biological changes included a 45% increase in platelet \u03b4-granules, higher mitochondrial counts, elevated gene expression (notably BDNF in women, p\u2009=\u20090.046), and modulation of oxidative stress markers (17% reduction in TBARS, 30% increase in GSH). Machine learning identified BDNF and PINK1 expression, along with MOCA and MMSE scores, as key predictors of UPDRS improvement. These findings suggest that neurotrophic peptide therapy may influence clinical, structural, and molecular domains in PD. Larger, controlled trials are warranted to confirm therapeutic potential and clarify associations with cognitive and neurotrophic parameters.<\/jats:p>","DOI":"10.1038\/s41531-026-01270-6","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:36:49Z","timestamp":1769200609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the neurotrophic peptide mixture in pathogenetic therapy of patients with Parkinson\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Dmytro","family":"Krasnienkov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Karaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Karasevych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliia","family":"Melnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergiy","family":"Kryzhanovskyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kateryna","family":"Rozova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Gonchar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Mankovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofiia","family":"Smovzh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostiantyn","family":"Midlovets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olexiy","family":"Barsukov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oksana","family":"Zabuha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana","family":"Papurina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neurol.2017.12.003","volume":"174","author":"A Alexoudi","year":"2018","unstructured":"Alexoudi, A., Alexoudi, I. & Gatzonis, S. Parkinson\u2019s disease pathogenesis, evolution and alternative pathways: A review. Rev. Neurol. (Paris) 174, 699\u2013704 (2018).","journal-title":"Rev. Neurol. (Paris)"},{"key":"1270_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/RLU.0000000000002251","volume":"201843","author":"SJ Chung","year":"2018","unstructured":"Chung, S. J. et al. The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease. Clin. Nucl. Med 201843, 787\u2013792 (2018).","journal-title":"Clin. Nucl. Med"},{"key":"1270_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","volume":"24","author":"HE Moon","year":"2015","unstructured":"Moon, H. E. & Paek, S. H. Mitochondrial Dysfunction in Parkinson\u2019s Disease. Exp. Neurobiol. 24, 103\u2013116 (2015).","journal-title":"Exp. Neurobiol."},{"key":"1270_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2967\/jnumed.119.228080","volume":"61","author":"A Mansur","year":"2020","unstructured":"Mansur, A. et al. Characterization of 3 PET tracers for quantification of mitochondrial andsynaptic function in healthy human brain:18F-BCPP-EF,11C-SA-4503, and11C-UCB-J. J. Nucl. Med 61, 96\u2013103 (2020).","journal-title":"J. Nucl. Med"},{"key":"1270_CR5","unstructured":"Simonenkov, A. P. & Kluyev, V. M. Syndrome serotonin deficiency. M.: BINOM, 96-97 (2013)."},{"key":"1270_CR6","first-page":"241","volume":"5","author":"R Mauricio","year":"2019","unstructured":"Mauricio, R. et al. Tackling gaps in developing life-changing treatments for dementia. Alzheimers Dement 5, 241\u2013253 (2019).","journal-title":"Alzheimers Dement"},{"key":"1270_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.15407\/ubj93.05.021","volume":"93","author":"OO Gonchar","year":"2021","unstructured":"Gonchar, O. O., Klymenko, O. O., Drevytska, T. I., Bratus, L. V. & Mankovska, I. M. Oxidative stress in rat heart mitochondria under a rotenone model of Parkinson\u2019 disease: a corrective effect of capicor treatment. Ukr. Biochem J. 93, 21\u201330 (2021).","journal-title":"Ukr. Biochem J."},{"key":"1270_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1162\/jocn.2009.21230","volume":"22","author":"NJ Schneider-Garces","year":"2010","unstructured":"Schneider-Garces, N. J. et al. Span, CRUNCH, and beyond: working memory capacity and the aging brain. J. Cogn. Neurosci. 22, 655\u2013669 (2010).","journal-title":"J. Cogn. Neurosci."},{"key":"1270_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s10072-021-05089-2","volume":"42","author":"B Fiani","year":"2021","unstructured":"Fiani, B. et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurol. Sci. 42, 1345\u20131353 (2021).","journal-title":"Neurol. Sci."},{"key":"1270_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14737175.2018.1500459","volume":"18","author":"M Brainin","year":"2018","unstructured":"Brainin, M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert Rev. Neurother. 18, 681\u2013687 (2018).","journal-title":"Expert Rev. Neurother."},{"key":"1270_CR11","doi-asserted-by":"crossref","unstructured":"Requeejoe, C. et al. Nanodelivery of Cerebrolysin and rearing enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson\u2019s disease. Mol Neurobiol. Springer Science+Business Media, LLC (2017).","DOI":"10.1007\/s12035-017-0741-x"},{"key":"1270_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lfs.2016.05.022","volume":"155","author":"A Neveen","year":"2016","unstructured":"Neveen, A. et al. A promising therapeutic potential of Cerebrolysin in the 6-OHDA rat model of Parkinson's disease. Life Sci 155, 174\u2013179 (2016).","journal-title":"Life Sci"},{"key":"1270_CR13","first-page":"27","volume":"2","author":"E Luchanina","year":"2011","unstructured":"Luchanina, E., Karaban, I. & Berezetskaya, N. Diagnosis of Parkinsonas disease by electrophysiological methods. Diagn. Rehabil. Parkinson. Dis. 2, 27\u201358 (2011).","journal-title":"Diagn. Rehabil. Parkinson. Dis."},{"key":"1270_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1023\/A:1016394031947","volume":"33","author":"P Eder","year":"2001","unstructured":"Eder, P., Reinprecht, I., Schreiner, E., Skofitsch, G. & Windisch, M. Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats. Histochem J. 33, 605\u2013612 (2001).","journal-title":"Histochem J."},{"key":"1270_CR15","first-page":"571","volume":"35","author":"M Stepanichev","year":"2017","unstructured":"Stepanichev, M. et al. Effects of cerebrolysin on nerve growth factor system in the aging rat brain. Restor. Neurol. Neurosci. 35, 571\u2013581 (2017).","journal-title":"Restor. Neurol. Neurosci."},{"key":"1270_CR16","first-page":"273","volume":"59","author":"I Veinbergs","year":"2000","unstructured":"Veinbergs, I., Mante, M., Mallory, M. & Masliah, E. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J. Neural Transm. Suppl. 59, 273\u2013280 (2000).","journal-title":"J. Neural Transm. Suppl."},{"key":"1270_CR17","unstructured":"Alvarez, X. A. et al. Neuroimmunotrophic effects of cerebrolysin in an animal model of hippocampal degeneration induced by \u03b2-amyloid. In: Korczyn, A. D., ed. International Congress on Vascular Dementia 2017. Bologna, Italy: Monduzzi Editore, 233\u2013237 (1999)."},{"key":"1270_CR18","first-page":"1","volume":"41","author":"SI Gavrilova","year":"2020","unstructured":"Gavrilova, S. I. & Alvarez, A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimeras disease: 30 years of clinical use. Med Res Rev. 41, 1\u201329 (2020).","journal-title":"Med Res Rev."},{"key":"1270_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/15459683211000734","volume":"35","author":"SR DeBoer","year":"2021","unstructured":"DeBoer, S. R. et al. Enhanced spontaneous motor recovery after stroke in mice treated with cerebrolysin. Neurorehabil Neural Repair 35, 525\u2013533 (2021).","journal-title":"Neurorehabil Neural Repair"},{"key":"1270_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s10072-019-04181-y","volume":"41","author":"DF Muresanu","year":"2020","unstructured":"Muresanu, D. F. et al. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial. Neurol. Sci. 41, 1171\u20131181 (2020).","journal-title":"Neurol. Sci."},{"key":"1270_CR21","doi-asserted-by":"publisher","DOI":"10.1590\/acb370605","volume":"37","author":"W Lu","year":"2022","unstructured":"Lu, W. et al. Cerebrolysin alleviates early brain injury after traumatic brain injury by inhibiting neuroinflammation and apoptosis via TLR signaling pathway. Acta Cir. Bras. 37, e370605 (2022).","journal-title":"Acta Cir. Bras."},{"key":"1270_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3109\/02688697.2013.793287","volume":"27","author":"CC Chen","year":"2013","unstructured":"Chen, C. C., Wei, S. T., Tsaia, S. C., Chen, X. X. & Cho, D. Y. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study. Br. J. Neurosurg. 27, 803\u2013807 (2013).","journal-title":"Br. J. Neurosurg."},{"key":"1270_CR23","first-page":"19","volume":"11","author":"S Cui","year":"2019","unstructured":"Cui, S. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 11, 19\u201320 (2019).","journal-title":"Cochrane Database Syst Rev."},{"key":"1270_CR24","first-page":"131","volume":"9","author":"E Rochenstein","year":"2015","unstructured":"Rochenstein, E. et al. Neuropeptide treatment with cerebrolysin enhances the survival of grafted neural stem cells in a synuclein transgenic model of Parkinson\u2019s disease. J. Exp. Neurosci. 9, 131\u2013140 (2015).","journal-title":"J. Exp. Neurosci."},{"key":"1270_CR25","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.clinph.2019.04.314","volume":"130","author":"D H\u00fcnerli","year":"2019","unstructured":"H\u00fcnerli, D. et al. Mild cognitive impairment in Parkinson\u2019s disease is associated with decreased P300 amplitude and reduced putamen volume. Clin. Neurophysiol. 130, 1208\u20131217 (2019).","journal-title":"Clin. Neurophysiol."},{"key":"1270_CR26","first-page":"281","volume":"59","author":"XA Alvarez","year":"2000","unstructured":"Alvarez, X. A., Lombardi, V. R., Fern\u00e1ndez-Novoa, L., Garc\u00eda, M. & Sampedro, C. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J. Neural Transm. 59, 281\u2013292 (2000).","journal-title":"J. Neural Transm."},{"key":"1270_CR27","first-page":"255","volume":"55","author":"VI Kulinski\u012d","year":"2009","unstructured":"Kulinski\u012d, V. I. & Kolesnichenko, L. S. Glutathione system. I. Synthesis, transport, glutathione transferases, glutathione peroxidases. Biomed. Khim 55, 255\u2013277 (2009).","journal-title":"Biomed. Khim"},{"key":"1270_CR28","first-page":"352","volume":"4","author":"NK Zenkov","year":"2001","unstructured":"Zenkov, N. K., Lankin, V. Z. & Menshikova, E. B. Oxidative stress: The biochemical and pathophysiological aspects. M.: MAIK. Science \/ Interperiodica 4, 352\u2013361 (2001).","journal-title":"M.: MAIK. Science \/ Interperiodica"},{"key":"1270_CR29","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1182\/blood.V100.7.2506","volume":"100","author":"SM Park","year":"2002","unstructured":"Park, S. M. et al. Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets. Blood 100, 2506\u20132514 (2002).","journal-title":"Blood"},{"key":"1270_CR30","doi-asserted-by":"publisher","first-page":"20704","DOI":"10.3390\/ijms160920704","volume":"16","author":"Y Luo","year":"2015","unstructured":"Luo, Y., Hoffer, A., Hoffer, B. & Qi, X. Mitochondria: A therapeutic target for Parkinson\u2019s disease?. Int J. Mol. Sci. 16, 20704\u201320730 (2015).","journal-title":"Int J. Mol. Sci."},{"key":"1270_CR31","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1016\/j.febslet.2015.09.031","volume":"589","author":"MH Voutilainen","year":"2015","unstructured":"Voutilainen, M. H., Arumae, U., Airavaara, M. & Saarma, M. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF\/MANF family of neurotrophic factors in Parkinson\u2019s disease. FEBS Lett. 589, 3739\u20133748 (2015).","journal-title":"FEBS Lett."},{"key":"1270_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1270_CR33","first-page":"493","volume":"13","author":"OI Filippova","year":"2012","unstructured":"Filippova, O. I., Koloskov, A. V. & Stolitsa, A. A. Methods for studying the functional activity of platelets (literature review). Transfusiology 13, 493\u2013514 (2012).","journal-title":"Transfusiology"},{"key":"1270_CR34","first-page":"1","volume":"5","author":"E LeDell","year":"2020","unstructured":"LeDell, E. & Posse, C. H2O AutoML: Scalable Automatic Machine Learning. J. Open Source Softw. 5, 1\u201310 (2020).","journal-title":"J. Open Source Softw."},{"key":"1270_CR35","doi-asserted-by":"crossref","unstructured":"Chen, J. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. Proc. 22nd ACM SIGKDD Int. Conf. Knowledge Discovery Data Mining, 785\u2013794 (2016).","DOI":"10.1145\/2939672.2939785"},{"key":"1270_CR36","first-page":"18","volume":"2","author":"A Liaw","year":"2002","unstructured":"Liaw, A. & Wiener, M. Classification and regression by random Forest. R. N. 2, 18\u201322 (2002).","journal-title":"R. N."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01270-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01270-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01270-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:08:39Z","timestamp":1771942119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01270-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01270-6","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}